---
schema_version: "secwatch.filing_event.v1"
accession: "0001753926-24-000474"
form_type: "8-K"
ticker: "VANI"
cik: "0001266806"
company_name: "Vivani Medical, Inc."
filed_at: "2024-03-06T23:59:59+00:00"
generated_at: "2026-06-05T02:24:40.588861+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Vivani Medical appoints Daniel Bradbury to Board; former Amylin CEO led first once-weekly GLP-1 drug

## Summary
- Daniel Bradbury appointed to board effective March 4, 2024, filling newly created vacancy expanding board from 5 to 6 members.
- Bradbury was CEO of Amylin Pharmaceuticals until its $7.1B acquisition by Bristol-Myers Squibb in 2012; Amylin secured first once-weekly GLP-1 approval (Bydureon).
- He will serve on Audit Committee; annual retainers: $35,000 for board, $10,000 for committee.
- His GLP-1 expertise aligns with Vivani's lead programs: six-month GLP-1 implants NPM-115 (obesity) and NPM-119 (type 2 diabetes).

## SEC filing metadata
- accession: 0001753926-24-000474
- form_type: 8-K
- ticker: VANI
- cik: 0001266806
- company_name: Vivani Medical, Inc.
- filed_at: 2024-03-06T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1266806/000175392624000474/0001753926-24-000474-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1266806/000175392624000474/g084105_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001753926-24-000474
- JSON: https://secwatch.observer/filing/0001753926-24-000474.json
- Plain text: https://secwatch.observer/filing/0001753926-24-000474.txt

## Key facts
- Executive change
  Daniel Bradbury was appointed as Director at Vivani Medical, Inc..
  - Action: appointed
  - Role: Director
  source text: unanimously appointed Daniel Bradbury to fill a newly created vacancy on the Board
  evidence_url: https://www.sec.gov/Archives/edgar/data/1266806/000175392624000474/0001753926-24-000474-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.